Early detection of cancer: Fluorophore-labeled cyclooxygenase-2 inhibitors for imaging of overexpression

Nov 07, 2013 by Edward Knaus
Early Detection of Cancer
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer

Molecules that bind and illuminate proteins specific to tumor cells are key to detecting cancer as early as possible. The cyclooxygenase-2 (COX-2) enzyme is just such a protein, as the concentration of COX-2 is greater in cancer cells than in adjacent normal tissues. Therefore, attaching a suitable fluorescent label to a selective COX-2 inhibitor would be an effective strategy for the noninvasive detection of tumors in which COX-2 levels are elevated.

As they report in ChemMedChem, a collaboration led by Frank Wuest, Edward Knaus, and colleagues at the University of Alberta in Canada resulted in an important compound in which a 7-nitrobenzofurazan (NBD) fluorescent label is linked to the well-known anti-inflammatory drug celecoxib (celecoxib–NBD conjugate). Biological studies showed that this conjugate is a potent and of COX-2, a COX-2-specific biomarker for fluorescence imaging of cancer, and a useful optical probe for targeted imaging of COX-2 in cells and small animals, as well as for clinical imaging of tissues suitable for topical or endoluminal illumination, such as esophagus and colon.

"These results will be of interest to researchers and clinicians with specialization in the use of fluorescent biomarkers for the imaging and/or diagnosis of disease states in which the COX-2 isozyme is expressed, such as ," says Knaus. This work marks a significant step forward in efforts to facilitate the detection and diagnosis of cancer as early as possible.

Explore further: Jumping hurdles in the RNA world

More information: Fluorophore-Labeled Cyclooxygenase-2 Inhibitors for the Imaging of Cyclooxygenase-2 Overexpression in Cancer: Synthesis and Biological Studies, ChemMedChem, dx.doi.org/10.1002/cmdc.201300355

add to favorites email to friend print save as pdf

Related Stories

Fluorescent compounds make tumors glow

Apr 29, 2010

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

Study: Celecoxib can cause arrhythmias

Jan 15, 2008

U.S. medical researchers have determined the anti-inflammatory drug celecoxib (Celebrex) can adversely affect heart rhythm in fruit fly and rat models.

Team discovers potential new way to treat anxiety

Aug 04, 2013

Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report ...

Imaging inflammation in the living brain

Sep 30, 2011

Inflammation occurs in the human brain during illnesses such as Alzheimer's disease, Parkinson’s disease, stroke and traumatic brain injury. Now, a research team in Japan has developed a probe that can ...

Recommended for you

Jumping hurdles in the RNA world

Nov 21, 2014

Astrobiologists have shown that the formation of RNA from prebiotic reactions may not be as problematic as scientists once thought.

New computer model sets new precedent in drug discovery

Nov 18, 2014

A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects - a challenge that has ...

Finding new ways to make drugs

Nov 18, 2014

Chemists have developed a revolutionary new way to manufacture natural chemicals and used it to assemble a scarce anti-inflammatory drug with potential to treat cancer and malaria.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.